Press Release (Revised)

Date: July 21, 2026 BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Revised Press Release on the Unaudited Consolidated Financial Results for the quarter ended June 30, 2026 Dear Sir/Ma’am With reference to our earlier submission dated July 21, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the Press Release on the Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2026, we wish to inform you that the Company has revised the said Press Release. Accordingly, please find enclosed herewith the revised Press Release, which supersedes and replaces the Press Release submitted earlier. The same is also available on the Company’s website at https://anthembio.com/ Thanking you, Yours truly, For Anthem Biosciences Limited (Formerly known as Anthem Biosciences Private Limited) Divya Prasad Company Secretary & Compliance Officer Membership No: A41438 Press Release: Anthem Q1FY27 Results Consolidated Revenue from Operations for the quarter stood at ₹4,182 Mn. EBITDA for the quarter was ₹1,755 Mn at 39.6% EBITDA Margins. PAT at ₹1,199 Mn, with PAT margins at 27.1%. Bengaluru, July 21, 2026: Anthem Biosciences Limited (BSE: 544449 | NSE: ANTHEM | INE0CZ201020), an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”), today announced unaudited Consolidated Financial Results for the quarter ended June 30, 2026 as approved by its Board of Directors. Q1FY27 Financial Highlights: Particulars (₹ Mn) Q1FY27 Q1FY26 YoY Q4FY26 QoQ FY26 Revenue from Operations 4,182 5,402 -22.6% 6,109 -31.5% 21,243 CRDMO 3,408 4,527 -24.7% 5,128 -33.5% 17,727 Specialty Ingredients 774 875 -11.5% 981 -21.1% 3,516 Other Income 249 228 9.2% 512 -51.4% 1,558 Total Revenues 4,431 5,630 -21.3% 6,622 -33.1% 22,801 EBITDA 1,755 2,143 -18.1% 3,184 -44.9% 9,896 Profit before tax before 1,446 1,862 -22.4% 2,769 -47.8% 8,486 exceptional items Exceptional Items – n.a n.a. n.a. (10) n.a. 244 impact of new labour code Profit before tax after 1,446 1,862 -22.4% 2,779 -48.0% 8,242 exceptional items Profit after tax 1,199 1,358 -11.7% 1,898 -36.8% 5,918 Q1FY27 Key Financial Highlights:  Consolidated Revenue from Operations was ₹4,182 Mn for the quarter o CRDMO business delivered ₹3,408 Mn revenues o Specialty Ingredients delivered ₹774 Mn revenues  EBITDA was ₹1,755 Mn, with EBITDA margins at 39.6% o EBITDA for Q1FY27 includes Other Income of ₹249 Mn (Q1FY26: ₹228 Mn)  Other Operating Income on account of forex gain (net) and RoDTEP incentives is ₹13 Mn (Q1FY26: ₹37 Mn)  Financial and other Non-Operating Income is ₹236 Mn (Q1FY26: ₹191 Mn)  PBT was ₹1,446 Mn  PAT (Profit After Tax) was ₹1,199 Mn, with PAT margins at 27.1% Commenting on the results, Ajay Bhardwaj, Chairman, MD and CEO, Anthem Biosciences Limited, said: “Our Q1FY27 quarterly results reflect timing shifts in deliveries to key customers. The underlying demand remains strong, and with a higher concentration of scheduled deliveries in the latter half of the year, we are positioned to capture that momentum. We remain firmly committed to sustaining revenue growth aligned with our long-term historical performance. On the margin front, we delivered year-on-year improvement across both EBITDA and PAT margins. Our disciplined focus on cost efficiencies, yield optimization, and employee productivity continues to reinforce our industry-leading margin profile, positioning us to sustain this performance through the year.” Earnings Call: Anthem Biosciences Limited will conduct earnings call at 11:30 am (IST) on 22nd July, 2026 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. Date and Time: 22nd July, 2026, 11:30 am (IST) / 2:00 am (EST) / 7:00 am (UK) / 2:00 pm (SGT/HKT) Universal Dial-in +91 22 6280 1102 / +91 22 7115 8003 International Dial-in Singapore: 8001012045 | HK: 800964448 | USA: 186674 62133 | UK: 08081011573 Diamond Pass link Diamond Pass Registration About Anthem: Incorporated in Bangalore on June 13, 2006, Anthem is an innovation-driven and technology- focused CRDMO with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem is one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, Anthem serves a range of customers, encompassing innovator- focused emerging biotech and large pharmaceutical companies globally. With the three pillars of innovation and technology, high quality standards, and a customer- first approach, Anthem is committed to solving problems in biology and chemistry using technology. For more information, please visit https://anthembio.com/investors/ For further details, please feel free to contact: investors.abl@anthembio.com Disclaimer: This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Anthem, nor our directors, assume any obligation to update any forward- looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.